BG-II is a medicine that helps kids who struggle to focus, sit still, or handle their feelings. Doctors often give it to kids who have ADHD or autism.
BG-II is a medicine that helps kids who struggle to focus, sit still, or handle their feelings. Doctors often give it to kids who have ADHD or autism.
How common is BG-II prescribed for kids with ADHD or autism?
BG-II is increasingly being prescribed for these conditions, particularly when other treatment options haven’t been effective.
Can BG-II be used along with other treatments?
Definitely! BG-II can be part of a multi-faceted treatment plan that includes behavioral therapies and educational support.
Can BG-II help with emotional regulation?
Yes, BG-II works on specific neurotransmitters in the brain that assist in emotional regulation.
BG-II is a medication primarily used to treat certain neurodevelopmental disorders, including Attention-Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). It acts on specific neurotransmitters in the brain to help regulate behavior, focus, and emotional responses. According to recent medical literature, BG-II has become a commonly prescribed medication for these conditions, especially when other treatment options have proven ineffective.
So, you’re thinking about BG-II for your child. It’s good to know what you’re getting into. Like most medications, BG-II comes with a few side effects. Here’s a quick rundown:
The upside is that these side effects often lessen over time as the body adjusts. Keep an open line with your healthcare provider, and you’ll be better equipped to manage these little bumps in the road.
While BG-II does its work in the brain, Goally can help reinforce positive behaviors and routines. If sleep becomes an issue with BG-II, for example, Goally’s digital visual scheduler can set up a calming bedtime routine. The app will walk your child through each step, from brushing teeth to reading a bedtime story, making sleep more inviting. It’s a win-win for both medication and tech!
| This post was originally published on September 9, 2023. |